Use of IMP3, S100P, and pVHL immunopanel to aid in the interpretation of bile duct biopsies with atypical histology or suspicious for malignancy

Applied Immunohistochemistry and Molecular Morphology

Volumn 20, Issue 5, 2012, Pages 478-487

  Schmidt, Michael T ^a   Himmelfarb, Eric A ^a   Shafi, Hedyeh ^a   Lin, Fan ^b   Xu, Haodong ^c   Wang, Hanlin L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GEISINGER MEDICAL CENTER   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Adenocarcinoma; Bile duct; Biopsy; IMP3; PVHL; S100P

Indexed keywords

INSULIN LIKE GROWTH FACTOR II MRNA BINDING PROTEIN 3; PROTEIN S 100; RNA BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 3; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ABDOMINAL PAIN; ADENOCARCINOMA; ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER DIAGNOSIS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; ENDOSCOPIC BIOPSY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; EPIGASTRIC PAIN; EPITHELIUM CELL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; JAUNDICE; LETHARGY; MALAISE; MALE; NAUSEA AND VOMITING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SATIETY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS; BIOPSY; CALCIUM-BINDING PROTEINS; ENDOSCOPY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM PROTEINS; RNA-BINDING PROTEINS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84866594363     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e318245e05b     Document Type: Article

References (43)

1. Allen PJ, Reiner AS, Gonen M, et al. Extrahepatic cholangiocarcinoma: a comparison of patients with resected proximal and distal lesions. HPB. 2008;10:341-346.
2. Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB. 2008;10:77-82.
3. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004;24:115-125.
4. Carpelan-Holmström M, Nordling S, Pukkala E, et al. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study reevaluating the data of the Finnish Cancer Registry. Gut. 2005; 54:385-387.
5. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567-579.
6. Malaguarnera G, Giordano M, Paladina I, et al. Markers of bile duct tumors. World J Gastrointest Oncol. 2011;3:49-59.
7. Tan G, Yilmaz A, De Young BR, et al. Immunohistochemical analysis of biliary tract lesions. Appl Immunohistochem Mol Morphol. 2004;12:193-197.
8. Karamitopoulou E, Tornillo L, Zlobec I, et al. Clinical significance of cell cycle- and apoptosis-related markers in biliary tract cancer: a tissue microarray-based approach revealing a distinctive immunophenotype for intrahepatic and extrahepatic cholangiocarcinomas. Am J Clin Pathol. 2008;130:780-786.
9. Argani P, Iacobuzio-Donahue C, Ryu B, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 2001;7:3862-3868.
10. Obama K, Ura K, Li M, et al. Genome-wide analysis of gene expression in human intrahepatic cholangiocarcinoma. Hepatology. 2005;41:1339-1348.
11. Swierczynski SL, Maitra A, Abraham SC, et al. Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Hum Pathol. 2004;35:357-366.
12. Tascilar M, Offerhaus GJ, Altink R, et al. Immunohistochemical labeling for the Dpc4 gene product is a specific marker for adenocarcinoma in biopsy specimens of the pancreas and bile duct. Am J Clin Pathol. 2001;116:831-837.
13. Zhao H, Davydova L, Mandich D, et al. S100A4 protein and mesothelin expression in dysplasia and carcinoma of the extrahepatic bile duct. Am J Clin Pathol. 2007;127:374-379.
14. Mall AS, Tyler MG, Ho SB, et al. The expression of MUC mucin in cholangiocarcinoma. Pathol Res Pract. 2010;206:805-809.
15. Levy M, Lin F, Xu H, et al. S100P, von Hippel-Lindau gene product, and IMP3 serve as a useful immunohistochemical panel in the diagnosis of adenocarcinoma on endoscopic bile duct biopsy. Hum Pathol. 2010;41:1210-1219.
16. Pryor JG, Bourne PA, Yang Q, et al. IMP-3 is a novel progression marker in malignant melanoma. Mod Pathol. 2008;21:431-437.
17. Lin F, Shi J, Liu H, et al. Diagnostic utility of S100P and von Hippel-Lindau gene product (pVHL) in pancreatic adenocarcinoma with implication of their roles in early tumorigenesis. Am J Surg Pathol. 2008;32:78-91.
18. Findeis-Hosey JJ, Xu H. The use of insulin like-growth factor II messenger RNA binding protein-3 in diagnostic pathology. Hum Pathol. 2011;42:303-314.
19. Mueller-Pillasch F, Pohl B, Wilda M, et al. Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev. 1999;88:95-99.
20. Müeller-Pillasch F, Lacher U, Wallrapp C, et al. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene. 1997;14:2729-2733.
21. Yantiss RK, Woda BA, Fanger GR, et al. KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol. 2005;29:188-195.
22. Zhao H, Mandich D, Cartun RW, et al. Expression of K homology domain containing protein overexpressed in cancer in pancreatic FNA for diagnosing adenocarcinoma of pancreas. Diagn Cytopathol. 2007;35:700-704.
23. Ligato S, Zhao H, Mandich D, et al. KOC (K homology domain containing protein overexpressed in cancer) and S100A4-protein immunoreactivity improves the diagnostic sensitivity of biliary brushing cytology for diagnosing pancreaticobiliary malignancies. Diagn Cytopathol. 2008;36:561-567.
24. Yantiss RK, Cosar E, Fischer AH. Use of IMP3 in identification of carcinoma in fine needle aspiration biopsies of pancreas. Acta Cytol. 2008;52:133-138.
25. Riener MO, Fritzsche FR, Clavien PA, et al. IMP3 expression in lesions of the biliary tract: a marker for high-grade dysplasia and an independent prognostic factor in bile duct carcinomas. Hum Pathol. 2009;40:1377-1383.
26. Schaeffer DF, Owen DR, Lim HJ, et al. Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) overexpression in pancreatic ductal adenocarcinoma correlates with poor survival. BMC Cancer. 2010;10:59.
27. Wachter DL, Schlabrakowski A, Hoegel J. Diagnostic value of immunohistochemical IMP3 expression in core needle biopsies of pancreatic ductal adenocarcinoma. Am J Surg Pathol. 2011;35:873-877.
28. Hart J, Parab M, Mandich D, et al. IMP3 immunocytochemical staining increases sensitivity in the routine cytologic evaluation of biliary brush specimens. Diagn Cytopathol. 2010. [Epub ahead of print].
29. Arumugam T, Logsdon CD. S100P: a novel therapeutic target for cancer. Amino Acids. 2011;41:893-899.
30. Kahn HJ, Marks A, Thom H, et al. Role of antibody to S100 protein in diagnostic pathology. Am J Clin Pathol. 1983;79:341-347.
31. Becker T, Gerke V, Kube E, et al. S100P, a novel Ca(2+)-binding protein from human placenta. cDNA cloning, recombinant protein expression and Ca2+ binding properties. Eur J Biochem. 1992;207:541-547.
32. Higgins JP, Kaygusuz G, Wang L, et al. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am J Surg Pathol. 2007;31:673-680.
33. Dowen SE, Crnogorac-Jurcevic T, Gangeswaran R, et al. Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer. Am J Pathol. 2005;166:81-92.
34. Ohuchida K, Mizumoto K, Egami T, et al. S100P is an early developmental marker of pancreatic carcinogenesis. Clin Cancer Res. 2006;12:5411-5416.
35. Sato N, Fukushima N, Matsubayashi H, et al. Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling. Oncogene. 2004;23:1531-1538.
36. Hamada S, Satoh K, Hirota M, et al. Calcium-binding protein S100P is a novel diagnostic marker of cholangiocarcinoma. Cancer Sci. 2011;102:150-156.
37. Aishima S, Fujita N, Mano Y, et al. Different roles of S100P overexpression in intrahepatic cholangiocarcinoma: carcinogenesis of perihilar type and aggressive behavior of peripheral type. Am J Surg Pathol. 2011;35:590-598.
38. Deng H, Shi J, Wilkerson M, et al. Usefulness of S100P in diagnosis of adenocarcinoma of pancreas on fine-needle aspiration biopsy specimens. Am J Clin Pathol. 2008;129:81-88.
39. Kosarac O, Takei H, Zhai QJ, et al. S100P and XIAP expression in pancreatic ductal adenocarcinoma: potential novel biomarkers as a diagnostic adjunct to fine needle aspiration cytology. Acta Cytol. 2011;55:142-148.
40. Dim DC, Jiang F, Qiu Q, et al. The usefulness of S100P, mesothelin, fascin, prostate stem cell antigen, and 14-3-3 sigma in diagnosing pancreatic adenocarcinoma in cytological specimens obtained by endoscopic ultrasound guided fine-needle aspiration. Diagn Cytopathol. 2011. [Epub ahead of print].
41. Clark PE, Cookson MS. The von Hippel-Lindau gene: turning discovery into therapy. Cancer. 2008;113(7 suppl):1768-1778.
42. Maher ER, Neumann HP, Richard S. von Hippel-Lindau disease: a clinical and scientific review. Eur J Hum Genet. 2011;19:617-623.
43. Lin F, Shi J, Liu H, et al. Immunohistochemical detection of the von Hippel-Lindau gene product (pVHL) in human tissues and tumors: a useful marker for metastatic renal cell carcinoma and clear cell carcinoma of the ovary and uterus. Am J Clin Pathol. 2008;129: 592-605.